Cathie Wood 購買 780 萬美元的 Moderna 疫苗股票，押注多元化管道和監管勝利

週二，Cathie Wood 的 Ark Invest 大幅增持了著名的 COVID-19 疫苗製造商 Moderna Inc. (MRNA) 的股份，因為這家生物技術公司即將迎來一系列催化劑。 Ark Invest 透過其旗艦 Ark Innovation ETF (ARKK) 購買了 72,800 股 Moderna 股票，價值約 782 萬美元。此舉表明 Ark Invest 對 Moderna 除了 mRNA COVID-19 疫苗之外的潛力繼續充滿信心，包括下一代 COVID-19 疫苗和其他有前途的候選疫苗。

Why Cathie Wood Just Bought $7.8 Million Worth of This COVID-19 Vaccine Stock

為什麼 Cathie Wood 剛剛購買了價值 780 萬美元的這種 COVID-19 疫苗股票

Embracing a "buy the dip" mentality, Cathie Wood's Ark Invest has significantly boosted its stake in Moderna Inc., a leading COVID-19 vaccine producer, with a strategic purchase of 72,800 shares. Priced at $107.41 each, this acquisition represents an investment of approximately $7.82 million.

Cathie Wood 的 Ark Invest 秉持著「逢低買入」的心態，大幅增持了領先的 COVID-19 疫苗生產商 Moderna Inc. 的股份，戰略性購買了 72,800 股。此次收購的單價為 107.41 美元，投資額約為 782 萬美元。

Betting on Moderna's Diversified Pipeline

押注 Moderna 的多元化產品線

Ark Invest's enthusiasm for Moderna extends beyond the firm's mRNA COVID-19 vaccine. The investment firm sees immense potential in Moderna's broader pipeline, including a next-generation COVID-19 vaccine and promising candidates in various therapeutic areas.

Ark Invest 對 Moderna 的熱情不僅限於該公司的 mRNA COVID-19 疫苗。該投資公司看到了 Moderna 更廣泛的產品線的巨大潛力，包括下一代 COVID-19 疫苗和各個治療領域有前途的候選疫苗。

Riding the Regulatory Wave

駕馭監管浪潮

With expectations of vaccine approvals and upcoming investor events, Ark Invest anticipates Moderna's stock to soar despite its recent market underperformance. Moderna's stock has declined by 26.89% over the past 12 months, but has rebounded by 8% since the start of 2024.

由於對疫苗批准和即將舉行的投資者活動的預期，Ark Invest 預計 Moderna 的股價將飆升，儘管其近期市場表現不佳。 Moderna 的股價在過去 12 個月內下跌了 26.89%，但自 2024 年初以來已反彈 8%。

Other Notable Trades

其他值得注意的交易

In addition to the Moderna purchase, ARKG, Ark's genomic revolution ETF, has shed 1,770 shares of Nvidia Corp. Valued at $1.63 million, this move signals a shift in focus within the ETF's portfolio.

除了收購 Moderna 之外，Ark 的基因組革命 ETF ARKG 還出售了 1,770 股 Nvidia 公司股票。價值 163 萬美元，此舉標誌著 ETF 投資組合的重點發生了轉變。

Meanwhile, ARKF, Ark's fintech innovation ETF, has acquired shares of Roblox Corp., while ARKG has expanded its holdings in Recursion Pharmaceuticals with a purchase of 60,9626 shares. On the other hand, ARKQ, Ark's autonomous technology and robotics ETF, has sold shares of Trimble Inc.

同時，Ark 的金融科技創新 ETF ARKF 收購了 Roblox Corp. 的股份，而 ARKG 則透過購買 60,9626 股擴大了 Recursion Pharmaceuticals 的持股。另一方面，Ark的自主技術和機器人ETF ARKQ已出售Trimble Inc.的股票。